

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF REGULATION 11 OF THE MARKET ABUSE  
(AMENDMENT) (EU EXIT) REGULATIONS 2019/310

19 February 2024

**Sabien Technology Group Plc**  
("Sabien", the "Company" or the "Group")

**Placement and Broker Option**

Sabien Technology Group (AIM:SNT) is pleased to announce that it has entered into a subscription agreement with Richard Parris, Executive Chairman and CEO of Sabien.

Under this agreement, Richard Parris will subscribe for new shares to be issued by the Company up to a total consideration of £40,000. The effective price of this new issue of equity will be determined by the average closing Sabien share price for the last five business days prior to the completion (the "**Subscription**").

In order to provide qualifying shareholders ("**Existing Shareholders**") and other qualified investors with an opportunity to participate on the same basis as the investment by Mr Parris, the Company has granted Peterhouse a Broker Option over such number of Ordinary Shares as agreed between the Company and Peterhouse. ("**Broker Option Shares**").

Existing Shareholders who hold Ordinary Shares in the Company and are on the register of members as at the close of business on 16 February 2024, will be given a priority right to participate in the Broker Option and all orders from such Existing Shareholders will be accepted and processed by Peterhouse, subject to scale-back under the Broker Option. The Broker Option has not been underwritten. Peterhouse is entitled to participate in the Broker Option as principal.

The Broker Option is exercisable by Peterhouse on more than one occasion, at any time from the time of this announcement to 5 p.m. UK time on 20 February 2024, at its absolute discretion, following consultation with the Company. There is no obligation on Peterhouse to exercise the Broker Option or to seek to procure subscribers for the Broker Option. Peterhouse may also allocate new Ordinary Shares after the time of any initial allocation to any person submitting a bid after that time.

The Broker Option Shares are not being made available to the public and none of the Broker Option Shares are being offered or sold in any jurisdiction where it would be unlawful to do so. No Prospectus will be issued in connection with the Broker Option.

To subscribe for Broker Option Shares, Existing Shareholders (who are qualifying) and other qualified investors should communicate their bid to Peterhouse via their stockbroker as Peterhouse cannot take direct orders from individual private investors. Existing Shareholders or other interested parties who wish to register their interest in participating in the Broker Option Shares should instruct their stockbroker to call Peterhouse on STX: 76086 or [020 7469 0938](tel:02074690938) or [020 7469 0936](tel:02074690936) or [020 7220 9797](tel:02072209797). Each bid should state the number of Broker Option Shares the Existing Shareholder wishes to subscribe for at the Issue Price.

For further information:

**Sabien Technology Group plc**  
Richard Parris, Executive Chairman  
Scott Fulton, Investor Relations

+44 20 7993 3700

[Scott.fulton@sabien.com](mailto:Scott.fulton@sabien.com)

**Allenby Capital Limited (Nominated Adviser)**  
John Depasquale / Nick Harriss / Vivek Bhardwaj

+44 203 328 5656

**Peterhouse Capital Limited (Broker)**  
Duncan Vasey / Lucy Williams

+44 207 469 0930

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

IOEIFFDFAIALIS